收稿日期: 2021-09-01
网络出版日期: 2021-08-25
随着我国社会经济的发展和人口老龄化进程的加速,与成功老龄化对应的老年性疾病对国民的影响日益突出,其中阿尔茨海默病（Aizheimer's disease,AD）及相关认知障碍尤为突出和显著。目前,中国AD发病率、患病率及死亡率仍持续增高,AD死亡占城乡居民总死亡原因的第5位,给居民和社会带来的经济负担日渐加重。为响应“健康中国行动”,促进由疾病治疗向健康维护转变,由上海交通大学医学院附属瑞金医院和中国疾病预防控制中心慢性非传染性疾病预防控制中心、复旦大学公共卫生学院、上海交通大学医学院附属精神卫生中心等单位专家联合编撰了本报告。本报告动态跟踪报道我国的AD流行趋势,综合评价我国的AD疾病经济负担,全面揭示我国的AD诊疗现状以及现有的相关公共卫生资源,旨在为AD的防治提供技术指导和支持,为政府制定相关卫生政策提供专业支持依据,为开展国际交流合作提供信息平台。
任汝静, 殷鹏, 王志会, 齐金蕾, 汤然, 王金涛, 黄强, 李建平, 谢心怡, 胡勇博, 崔诗爽, 余小萍, 朱圆, 刘馨雅, 朱怡康, 林绍慧, 王怡然, 黄延焱, 胡以松, 王学锋, 王鸿利, 褚敬申, 王颖, 李春波, 周脉耕, 王刚, 代表中国阿尔茨海默病报告编写组 . 中国阿尔茨海默病报告2021[J]. 诊断学理论与实践, 2021 , 20(04) : 317 -337 . DOI: 10.16150/j.1671-2870.2021.04.001
| [1] | 国家统计局. 第七次全国人口普查公报(第五号)[R/OL]. 2021[2021-09-01]. http://www.stats.gov.cn/tjsj/zxfb/202105/t20210510_1817181.html. |
| [2] | Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019,394(10204):1145-1158. |
| [3] | Zhang YQ, Wang CF, Xu G, et al. Mortality of Alzheimer′s Disease Patients: A 10-Year Follow-up Pilot Study in Shanghai[J]. Can J Neurol Sci, 2020,47(2):226-230. |
| [4] | Jia L, Du Y, Chu L, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study[J]. Lancet Public Health, 2020,5(12):e661-e671. |
| [5] | Jia J, Wei C, Chen S, et al. The cost of Alzheimer′s disease in China and re-estimation of costs worldwide[J]. Alzheimers Dement, 2018,14(4):483-491. |
| [6] | 中国保健老年协会阿尔兹海默病分会. 2019中国阿尔兹海默病患者家庭生存状况调研报告[R]. 人民日报社, 2020. |
| [7] | 中国阿尔茨海默病患者诊疗现状调研报告[R]. 第十三届健康中国论坛, 2021. |
| [8] | 健康中国行动(2019—2030年)[R/OL]. 2019-07-15[2021-09-01]. http://www.gov.cn/xinwen/2019-07/15/content_5409694.htm. |
| [9] | Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012,380(9859):2163-2196. |
| [10] | GBD 2013 DALYs and HALE Collaborators, Murray CJ, Barber RM, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition[J]. Lancet,2015, 386(10009):2145-2191. |
| [11] | World Health Organization. Global action plan on the public health response to dementia 2017-2025[J/OL]. 2017-12-07[2021-09-01]. https://www.who.int/publications/i/item/global-action-plan-on-the-public-health-response-to-dementia-2017---2025. |
| [12] | Slot RER, Sikkes SAM, Berkhof J, et al. Subjective cognitive decline and rates of incident Alzheimer′s disease and non-Alzheimer′s disease dementia[J]. Alzheimers Dement, 2019,5(3):465-476. |
| [13] | Alzheimer’s disease is the most common form of dementia, affecting up to 70% of all people with dementia[R/OL]. [2021-09-01]. https://www.dementia.org.au/about-dementia/types-of-dementia/alzheimers-disease. |
| [14] | Chandra A, Dervenoulas G, Politis M, et al. Magnetic resonance imaging in Alzheimer′s disease and mild cognitive impairment[J]. J Neurol, 2019,266(6):1293-1302. |
| [15] | 王刚, 吕发金. 痴呆及相关认知障碍的神经影像学诊断流程建议[J]. 重庆医科大学学报, 2017,42(6):684-686. |
| [16] | Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer′s disease[J]. Alzheimers Dement, 2018,14(4):535-562. |
| [17] | 陈永洪. 以β淀粉样蛋白为靶点治疗阿尔茨海默病的临床药物试验研究进展[J]. 国际神经病学神经外科学杂志, 2018,45(3):315-319. |
| [18] | 韩璎, 管一晖, 郭起浩, 等. 阿尔茨海默病18F-AV45 PET脑显像的操作技术和临床应用[J]. 中华神经医学杂志, 2021,20(1):2-7. |
| [19] | 常燕, 杨晖, 姚树林, 等. 视觉定性评估法与半定量分析法在18F-florbetaben β-淀粉样蛋白显像中的准确性比较[J]. 中华核医学与分子影像杂志, 2021,41(1):23-27. |
| [20] | Chandra A, Valkimadi PE, Pagano G, et al. Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer′s disease and mild cognitive impairment[J]. Hum Brain Mapp, 2019,40(18):5424-5442. |
| [21] | 北京认知神经科学学会, 上海医师协会老年医学科医师分会. 非痴呆人群淀粉样蛋白正电子发射断层显像扫描临床研究结果披露过程的中国专家共识[J]. 中华老年医学杂志, 2021,40(7):822-827. |
| [22] | Braak H, Braak E. Staging of Alzheimer′s disease-related neurofibrillary changes[J]. Neurobiol Aging, 1995,16(3):271-278. |
| [23] | 于倩, 李钰莹, 彭程. Tau蛋白显像剂的研究进展[J/OL]. 同位素, 2021-04-16[2021-09-01]. https://wap.cnki.net/touch/web/Journal/Article/TWSZ20210415003.html. |
| [24] | 陈怡静, 葛璟洁, 鲁佳荧, 等. 阿尔茨海默病患者脑内基于[18F]-APN-1607 PET显像的tau蛋白沉积与脑皮质萎缩的相关性研究[J]. 中国临床神经科学, 2021,29(4):380-386. |
| [25] | 李明, 鲁佳荧, 李玲, 等. [18F]-APN-1607 PET在痴呆患者脑内tau蛋白显像中的初步临床应用[J]. 中国临床神经科学, 2020,28(5):488-493. |
| [26] | 王瑞民, 田嘉禾, 贾建军, 等. 阿尔茨海默病与血管性痴呆的18F-FDG PET脑显像[J]. 中华核医学杂志, 2004,24(1):30-32. |
| [27] | Mayblyum DV, Becker JA, Jacobs HIL, et al. Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease[J]. Neurology, 2021,96(24):e2933-e2943. |
| [28] | 中华医学会老年医学分会老年神经病学组, 记忆门诊操作规程撰写专家组. 记忆门诊标准操作规程指南[J]. 中华老年医学杂志, 2015,34(8):819-828. |
| [29] | 中华医学会神经病学分会神经心理与行为神经病学学组. 常用神经心理认知评估量表临床应用专家共识[J]. 中华神经科杂志, 2019,52(3):166-176. |
| [30] | 郭起浩, 王刚, 武力勇. 痴呆及相关认知障碍的神经心理诊断流程[J]. 重庆医科大学学报, 2019,44(4):393-396. |
| [31] | 王刚. 痴呆及认知障碍神经心理测评量表手册[M]. 第二版. 北京: 科学出版社, 2021. |
| [32] | Fang R, Wang G, Huang Y, et al. Validation of the Chinese version of Addenbrooke′s cognitive examination-revised for screening mild Alzheimer′s disease and mild cognitive impairment[J]. Dement Geriatr Cogn Disord, 2014,37(3-4):223-231. |
| [33] | Huang YY, Qian SX, Guan QB, et al. Comparative study of two Chinese versions of Montreal Cognitive Assessment for Screening of Mild Cognitive Impairment[J]. Appl Neuropsychol Adult, 2021,28(1):88-93. |
| [34] | 玄令美, 颛孙雯, 陈梦婷, 等. 虚拟现实技术在老年痴呆患者中的研究进展[J]. 护理学报, 2019,26(3):17-19. |
| [35] | 贾芷莹, 董旻晔, 施贞夙, 等. 基于机器学习的轻度认知功能障碍动态优化筛查系统的探索研究[D]. 上海交通大学, 2019. |
| [36] | 孟秋艳, 尹惠茹, 王硕, 等. 老年轻度认知障碍患者计算机化认知筛查测试的研究进展[J]. 中华护理杂志, 2019,54(7):1023-1027. |
| [37] | Qiao Y, Xie XY, Lin GZ, et al. Computer-Assisted Speech Analysis in Mild Cognitive Impairment and Alzheimer′s Disease: A Pilot Study from Shanghai, China[J]. J Alzheimers Dis, 2020,75(1):211-221. |
| [38] | 贾建平, 王荫华, 章军建, 等. 中国痴呆与认知障碍诊治指南(四):辅助检查及其选择[J]. 中华医学杂志, 2011,91(13):867-875. |
| [39] | Bjerke M, Engelborghs S. Cerebrospinal Fluid Biomar-kers for Early and Differential Alzheimer′s Disease Diagnosis[J]. J Alzheimers Dis, 2018,62(3):1199-1209. |
| [40] | 曾凡, 张吉强, 王延江. 体液生物标记物在阿尔茨海默病早期诊断中的作用与评价[J]. 中国神经精神疾病杂志, 2011,37(4):244-246. |
| [41] | Ritchie C, Smailagic N, Noel-Storr AH, et al. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer′s disease dementia and other dementias in people with mild cognitive impairment (MCI)[J]. Cochrane Database Syst Rev, 2017,3(3):CD010803. |
| [42] | Janelidze S, Stomrud E, Smith R, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer′s disease[J]. Nat Commun, 2020,11(1):1683. |
| [43] | 孙广英, 薛敏. 阿尔茨海默病生物标志物的研究进展[J]. 中华神经医学杂志, 2018,17(11):1172-1176. |
| [44] | Moscoso A, Grothe MJ, Ashton NJ, et al. Time course of phosphorylated-tau181 in blood across the Alzheimer′s disease spectrum[J]. Brain, 2021,144(1):325-339. |
| [45] | Jia L, Zhu M, Kong C, et al. Blood neuro-exosomal synaptic proteins predict Alzheimer′s disease at the asymptomatic stage[J]. Alzheimers Dement, 2021,17(1):49-60. |
| [46] | Ma L, Wang R, Han Y, et al. Development of a Novel Urine Alzheimer-Associated Neuronal Thread Protein ELISA Kit and Its Potential Use in the Diagnosis of Alzheimer′s Disease[J]. J Clin Lab Anal, 2016,30(4):308-314. |
| [47] | 车向前, 谢心怡, 王刚, 等. 阿尔茨海默病及相关认知障碍基因检测的临床策略[J]. 重庆医科大学学报, 2021,46(7):804-808. |
| [48] | Gao Y, Ren RJ, Zhong ZL, et al. Mutation profile of APP, PSEN1, and PSEN2 in Chinese familial Alzheimer′s di-sease[J]. Neurobiol Aging, 2019,77:154-157. |
| [49] | 卢晓雄, 吕清, 浦佳丽, 等. 阿尔茨海默病患者早老素-1基因突变检测及其突变后对早老素-1和淀粉样前体蛋白表达功能的影响[J]. 中华神经科杂志, 2013,46(1):5-9. |
| [50] | Neu SC, Pa J, Kukull W, et al. Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis[J]. JAMA Neurol, 2017,74(10):1178-1189. |
| [51] | Wang J, Lu R, Yang J, et al. TRPC6 specifically inte-racts with APP to inhibit its cleavage by γ-secretase and reduce Aβ production[J]. Nat Commun, 2015,6:8876. |
| [52] | Lu R, Wang J, Tao R, et al. Reduced TRPC6 mRNA levels in the blood cells of patients with Alzheimer′s disease and mild cognitive impairment[J]. Mol Psychiatry, 2018,23(3):767-776. |
| [53] | Chen JM, Li QW, Liu JS, et al. TRPC6 mRNA levels in peripheral leucocytes of patients with Alzheimer′s di-sease and mild cognitive impairment: A case-control study[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2019,92:279-284. |
| [54] | Hansson O, Seibyl J, Stomrud E, et al. CSF biomarkers of Alzheimer′s disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts[J]. Alzheimers Dement, 2018,14(11):1470-1481. |
| [55] | Schindler SE, Gray JD, Gordon BA, et al. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging[J]. Alzheimers Dement, 2018,14(11):1460-1469. |
| [56] | Blennow K, Shaw LM, Stomrud E, et al. Predicting clinical decline and conversion to Alzheimer′s disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays[J]. Sci Rep, 2019,9(1):19024. |
| [57] | Santangelo R, Masserini F, Agosta F, et al. CSF p-tau/Aβ 42 ratio and brain FDG-PET may reliably detect MCI "imminent" converters to AD[J]. Eur J Nucl Med Mol Imaging, 2020,47(13):3152-3164. |
| [58] | 田金洲. 中国痴呆诊疗指南[M]. 人民卫生出版社, 北京: 2018:200-219. |
| [59] | Zhang Y, Li Y, Ma L. Recent advances in research on Alzheimer′s disease in China[J]. J Clin Neurosci, 2020,81:43-46. |
| [60] | Athar T, Al Balushi K, Khan SA. Recent advances on drug development and emerging therapeutic agents for Alzheimer′s disease[J]. Mol Biol Rep, 2021,48(7):5629-5645. |
| [61] | Lalli G, Schott JM, Hardy J, et al. Aducanumab: a new phase in therapeutic development for Alzheimer′s disease?[J]. EMBO Mol Med, 2021,13(8):e14781. |
| [62] | Xiao S, Chan P, Wang T, et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer′s dementia[J]. Alzheimers Res Ther, 2021,13(1):62. |
| [63] | Wang T, Kuang W, Chen W, et al. A phase Ⅱ randomi-zed trial of sodium oligomannate in Alzheimer′s dementia[J]. Alzheimers Res Ther, 2020,12(1):110. |
| [64] | Tolar M, Abushakra S, Hey JA, et al. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer′s disease with potential for near term approval[J]. Alzheimers Res Ther, 2020,12(1):95. |
| [65] | Perlmutter JS. Aducanumab: look before leaping[J]. Nat Med, 2021,27(9):1499. |
| [66] | Rubin R. Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered[J]. JAMA, 2021,326(6):469-472. |
| [67] | Selkoe DJ. Treatments for Alzheimer′s disease emerge[J]. Science, 2021,373(6555):624-626. |
| [68] | Zhang ZX, Hong Z, Wang YP, et al. Rivastigmine Patch in Chinese Patients with Probable Alzheimer′s disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily)[J]. CNS Neurosci Ther, 2016,22(6):488-496. |
| [69] | Wessels AM, Tariot PN, Zimmer JA, et al. Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials[J]. JAMA Neurol, 2020,77(2):199-209. |
| [70] | Im JJ, Jeong H, Bikson M, et al. Effects of 6-month at-home transcranial direct current stimulation on cognition and cerebral glucose metabolism in Alzheimer′s disease[J]. Brain Stimul, 2019,12(5):1222-1228. |
| [71] | Reilmann R, McGarry A, Grachev ID, et al. Safety and efficacy of pridopidine in patients with Huntington's di-sease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study[J]. Lancet Neurol, 2019,18(2):165-176. |
| [72] | Vasic V, Barth K, Schmidt MHH. Neurodegeneration and Neuro-Regeneration-Alzheimer′s Disease and Stem Cell Therapy[J]. Int J Mol Sci, 2019,20(17):4272. |
| [73] | 孟胜喜. 恒清Ⅱ号方联合盐酸多奈哌齐对阿尔茨海默病患者的疗效及其作用机制[J]. 中国医药导报, 2021,18(3):140-144. |
| [74] | Jia Y, Zhang X, Yu J, et al. Acupuncture for patients with mild to moderate Alzheimer′s disease: a randomized controlled trial[J]. BMC Complement Altern Med, 2017,17(1):556. |
| [75] | 葛宝金. 基于炎症因子叶酸与维生素B12联合对阿尔茨海默病患者干预的随机对照研究[D]. 天津医科大学, 2019. |
| [76] | 胡月青, 吕继辉, 王嫱, 等. 音乐疗法联合强光治疗对阿尔茨海默病患者睡眠障碍的疗效观察[J]. 首都医科大学学报, 2021,42(3):367-372. |
| [77] | 沈开艳. 上海蓝皮书:上海经济发展报告(2017)[M]. 北京: 社会科学文献出版社, 2017. |
| [78] | 任汝静, 王刚, 陈生弟. 对构建我国规范化记忆门诊的思考和展望[J]. 内科理论与实践, 2015,10(2):90-91. |
| [79] | 杨艺超. 我国长期护理保险模式优化探索——基于上海、青岛、南通三种模式的比较[J]. 现代商贸工业, 2021,42(23):83-85. |
| [80] | 舒露, 王群. 我国长期护理保险失智老人保障政策研究[J]. 卫生经济研究, 2020,37(11):7-10. |
| [81] | 贾云竹. 认知障碍照护服务发展现状与思考[J]. 社会福利, 2021,30(5):33-35. |
| [82] | 李文杰. 中国农村老年人口长期照护问题研究[D]. 河南大学, 2012. |
| [83] | 刘娟. 38例老年痴呆患者住院期间护理安全分析[J]. 解放军医院管理杂志, 2015,22(6):569-570. |
| [84] | 黄灿, 王爱民. 中重度老年痴呆住院患者的安全护理[J]. 医学信息, 2013,27(7):356-357. |
| [85] | 周和玲, 范卉, 吕敏敏. 团队协作模式在老年痴呆病人安全管理中的实践[J]. 全科护理, 2016,14(13):1366-1368. |
| [86] | 刘灿泳. 上海失智老人的社会支持研究[D]. 上海工程技术大学, 2020. |
/
| 〈 |
|
〉 |
